Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy-Reference-Cited by-同舟云学术

Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy

Published:2023 Issue:21 Volume:4 Page:5224-5237
ISSN:2633-5409
Container-title:Materials Advances
language:en
Short-container-title:Mater. Adv.

Author:

Malathi S.¹,Sisila Valappil²,Singaravel V.³,Venkatesan Nandakumar⁴⁵,Pakrudheen Iqbal⁶⁷,Dhanaraj R.³,Ayyadurai Niraikulam²,Bhuvarahamurthy V.³,Kalkura S. Narayana¹^ORCID

Affiliation:

1. Crystal Growth Centre, Anna University, Guindy, Chennai 600025, India

2. Biochemistry & Biotechnology, CSIR-Central Leather Research Institute, Adyar, Chennai 600020, India

3. Department of Medical Biochemistry, Post-graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai 600113, India

4. Department of Pediatrics, Obstetrics, and Gynaecology, University of Valencia, Valencia, 46010, Spain

5. Sri Ramachandra Faculty of Engineering and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai 600116, India

6. Department of Chemistry, CMR Institute of Technology, Bengaluru 560037, India

7. Centre of Excellence- Sensors & Nanoelectronics, CMR Institute of Technology, Bengaluru 560037, India

Abstract

NIODVC (cetuximab-conjugated doxorubicin and vitexin loaded niosome) proves effective for targeted breast cancer therapy. Enhanced cytotoxicity, cellular uptake, and gene downregulation show promise.

Funder

University Grants Commission

University of Madras

Council of Scientific and Industrial Research, India

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Chemistry (miscellaneous)

Link

http://pubs.rsc.org/en/content/articlepdf/2023/MA/D3MA00328K

Reference76 articles.

1. Understanding breast cancer as a global health concern